Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Influenza Other Respir Viruses. 2024 Sep;18(9):e70002. doi: 10.1111/irv.70002.
This retrospective cohort study analyzed data from a Japanese health insurance database to assess the effectiveness of baloxavir (n = 4822) for preventing severe events compared with oseltamivir (n = 10,523) in patients with influenza B. The primary endpoint was hospitalization incidence (Days 2-14). The secondary endpoints included intravenous antibacterial drug use, pneumonia hospitalization, heart failure hospitalization, inhalational oxygen requirement, and use of other anti-influenza drugs. The hospitalization incidence was significantly lower with baloxavir (0.15% vs. 0.37%; risk ratio: 2.48, 95% confidence interval: 1.13-5.43). Pneumonia and additional anti-influenza therapy were also less frequent with baloxavir, thus supporting its use. Trial Registration: UMIN Clinical Trials Registry Study ID: UMIN000051382.
本回顾性队列研究分析了来自日本医保数据库的数据，以评估巴洛沙韦（n=4822）与奥司他韦（n=10523）相比在预防流感 B 患者发生严重事件方面的有效性。主要终点为住院发生率（第 2-14 天）。次要终点包括静脉用抗菌药物使用、肺炎住院、心力衰竭住院、吸入氧气需求以及其他抗流感药物的使用。巴洛沙韦的住院发生率显著更低（0.15% vs. 0.37%；风险比：2.48，95%置信区间：1.13-5.43）。肺炎和其他抗流感治疗的发生频率也较低，因此支持使用巴洛沙韦。试验注册：UMIN 临床试验注册研究 ID：UMIN000051382。
